AfsanehBarziMDPhD
Oncology • Los Angeles, CAGastrointestinal Cancer
Associate Professor of Medical Oncology, City of Hope Comprehensive Cancer Center
Dr. Barzi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1441 Eastlake Ave
Nor 8302e
Los Angeles, CA 90033Phone+1 323-865-3105Fax+1 323-865-0061
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2001 - 2004
Tehran University of Medical Sciences School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 2011 - 2025
NV State Medical License 2023 - 2025
AK State Medical License 2022 - 2024
RI State Medical License 2021 - 2024
OH State Medical License 2008 - 2011
TX State Medical License 2005 - 2008- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
Clinical Trials
- Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer Start of enrollment: 2013 Aug 02
- Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Start of enrollment: 2015 Mar 01
- 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Start of enrollment: 2018 Feb 27
- Join now to see all
Publications & Presentations
PubMed
- 2867 citationsColorectal cancer statistics, 2017.Rebecca L. Siegel, Kimberly D. Miller, Stacey A. Fedewa, Dennis J. Ahnen, Reinier G.S. Meester
CA. 2017-05-06 - 22 citationsRandomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancerRichard D. Kim, Shannon McDonough, Anthony B. El-Khoueiry, Tanios Bekaii-Saab, Stacey M. Stein
European Journal of Cancer. 2020-05-01 - 19 citationsTelemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?Howard Jack West, Afsaneh Barzi, Debra Wong
Current Oncology Reports. 2022-12-01
Lectures
- Patient-reported outcomes (PRO) before and after colorectal cancer (CRC) by race in a national survey.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Total cost of care for patients (pts) with stage II colon cancer (CC-II): A SEER-Medicare analysis.2019 ASCO Annual Meeting - 6/1/2019
- Potential Role of Polymorphisms in the Transporter Genes ENT1 and MATE1/OCT2 in Predicting TAS-102 Efficacy and Toxicity in Patients with Refractory Metastatic Colorec...2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Colorectal Cancer Screening Uptake Tripled in 45-49 Age GroupOctober 3rd, 2024- Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-Mutated Metastatic Colorectal Cancer on September 8, 2021August 25th, 2021
Trovagene : Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer Trial Abstract for Presentation at the 2020 ASCO Annual MeetingJune 16th, 2020- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
